Literature DB >> 18802321

Influence of pH conditions on the viability of Saccharomyces boulardii yeast.

Sandrine Graff1, Jean-Claude Chaumeil, Pierre Boy, René Lai-Kuen, Christine Charrueau.   

Abstract

Saccharomyces boulardii is a probiotic with proven health benefits. However its survival is challenged by gastrointestinal transit, and a ratio between 1 and 3% of living yeast is recovered in the feces after oral administration. The aim of the study was to determine to what extent the yeast was sensitive to gastrointestinal pH conditions. Therefore we explored the survival of different concentrations of S. boulardii in conditions mimicking the stomach pH (pH 1.1 0.1 N HCl) and the intestinal pH (pH 6.8 phosphate buffer) in vitro. The probiotic being commercialized as a freeze-dried powder obtained from an aqueous suspension, both forms were evaluated. In phosphate buffer pH 6.8, the viability remained stable for both forms of S. boulardii for 6 h. In HCl pH 1.1, viability of both forms (200 mg L(-1)) significantly decreased from 5 min. Observation under scanning/transmission electron microscopy showed morphological damages and rupture of the yeast wall. Threshold value from which S. boulardii viability was unaltered was pH 4. At the highest concentration of 200 g L(-1), the initial pH value of 1.1 rose to 3.2, exerting a protective effect. In conclusion, although the yeast in aqueous suspension was less sensitive than the freeze-dried yeast to acidic conditions, a gastric protection for improvement of oral bioavailability of viable S. boulardii appears necessary.

Entities:  

Mesh:

Year:  2008        PMID: 18802321     DOI: 10.2323/jgam.54.221

Source DB:  PubMed          Journal:  J Gen Appl Microbiol        ISSN: 0022-1260            Impact factor:   1.452


  13 in total

Review 1.  Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.

Authors:  Lynne V McFarland
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  Use of artificial digestive systems to investigate the biopharmaceutical factors influencing the survival of probiotic yeast during gastrointestinal transit in humans.

Authors:  Stéphanie Blanquet-Diot; Sylvain Denis; Sandrine Chalancon; Fehd Chaira; Jean-Michel Cardot; Monique Alric
Journal:  Pharm Res       Date:  2011-11-09       Impact factor: 4.200

3.  A Tunable and Expandable Transactivation System in Probiotic Yeast Saccharomyces boulardii.

Authors:  Suryang Kwak; Bejan Mahmud; Gautam Dantas
Journal:  ACS Synth Biol       Date:  2021-12-23       Impact factor: 5.249

4.  Oral administration of Saccharomyces boulardii ameliorates carbon tetrachloride-induced liver fibrosis in rats via reducing intestinal permeability and modulating gut microbial composition.

Authors:  Ming Li; Lin Zhu; Ao Xie; Jieli Yuan
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

5.  Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders.

Authors:  Theodoros Kelesidis; Charalabos Pothoulakis
Journal:  Therap Adv Gastroenterol       Date:  2012-03       Impact factor: 4.802

Review 6.  Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis - a review.

Authors:  Margret I Moré; Alexander Swidsinski
Journal:  Clin Exp Gastroenterol       Date:  2015-08-14

Review 7.  Saccharomyces boulardii CNCM I-745 Improves Intestinal Enzyme Function: A Trophic Effects Review.

Authors:  Margret I Moré; Yvan Vandenplas
Journal:  Clin Med Insights Gastroenterol       Date:  2018-02-09

8.  S-Adenosyl-L-methionine protects the probiotic yeast, Saccharomyces boulardii, from acid-induced cell death.

Authors:  Vincent Cascio; Daniel Gittings; Kristen Merloni; Matthew Hurton; David Laprade; Nicanor Austriaco
Journal:  BMC Microbiol       Date:  2013-02-13       Impact factor: 3.605

9.  Dynamic In Vitro Models of the Human Gastrointestinal Tract as Relevant Tools to Assess the Survival of Probiotic Strains and Their Interactions with Gut Microbiota.

Authors:  Charlotte Cordonnier; Jonathan Thévenot; Lucie Etienne-Mesmin; Sylvain Denis; Monique Alric; Valérie Livrelli; Stéphanie Blanquet-Diot
Journal:  Microorganisms       Date:  2015-10-23

10.  Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice.

Authors:  Amandine Everard; Sébastien Matamoros; Lucie Geurts; Nathalie M Delzenne; Patrice D Cani
Journal:  mBio       Date:  2014-06-10       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.